… Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure
vaccine … Human papillomavirus vaccination coverage among adolescents, 2007-2013, …

BACKGROUND Cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ (CIN2+)
lesions can be monitored as early indicators of human papillomavirus (HPV) vaccine …

… Human papillomavirus (HPV) vaccination is expected to reduce the burden of cervical cancer
in … of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25 5399–408. …

… Prevalence ratios (PRs) for each vaccine era compared with the prevaccine era were
used … of vaccine era overall vs. prevaccine era overall), impact among vaccinated persons (…

The adolescent health community must act quickly in the face of the COVID-19 pandemic to
protect hard-won gains in human papillomavirus (HPV) vaccination coverage. HPV vaccine …

… Pre-vaccination Era and between 25 and 29 years among men. Human papillomaviruses
(… virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in …

• Two prophylactic vaccines, Gardasil and Cervarix, offer protection against HPV types 16 and
18. These 2 genotypes are responsible for about 70% of cervical cancers• These vaccines …

… 18 infection in vaccine era compared with prevaccine era. C , … /18 infection in vaccine era
compared with prevaccine era or … /11 infection in vaccine era compared with prevaccine era. In …

… 16/18/vaccines have been approved. The development of prophylactic vaccines against human
… to reduce dramatically the mortality of human papilomavirus associated cancers, but has …

… incidence of non-SCC was markedly decreased in the vaccine era compared with prevaccine
era among young females aged 15–24 years. Therefore, the temporal association of HPV …